Is VIAP or JNJ a better dividend investment in 2026?

VIAP currently yields 400000.00% with a 5% 5-year dividend growth rate. JNJ yields 3.36% with 5.8% growth. The better choice depends on your goal: VIAP offers higher current income.

What is the dividend yield difference between VIAP and JNJ?

VIAP has a forward dividend yield of 400000.00% ($2.00/share annually). JNJ yields 3.36% ($4.96/share annually). The yield gap is 399996.64 percentage points.

Home › Compare › VIAP vs JNJ

VIAP vs JNJ: Dividend Comparison 2026

VIAP yields 400000.00% · JNJ yields 3.36%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 VIAP wins by $5.011119029548644e+32M in total portfolio value

INVESTMENT

TIME HORIZON10 years

VIAP

● Live price

400000.00%

Share price

$0.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$5.011119029548644e+32M

Annual income

$500,865,583,351,836,840,000,000,000,000,000,000,000.00

Full VIAP calculator →

JNJ

Johnson & Johnson

● Live price

3.36%

Share price

$147.50

Annual div

$4.96

5Y div CAGR

5.8%

Payout ratio

55%

After 10 yrs · $10,000 · DRIP

Portfolio value

$20.0K

Annual income

$827.78

Full JNJ calculator →

Portfolio growth — VIAP vs JNJ

📍 VIAP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	VIAP	JNJ
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, VIAP + JNJ cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

VIAP pays

JNJ pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VIAP

Annual income on $10K today (after 15% tax)

$34,000,000.00/yr

After 10yr DRIP, annual income (after tax)

$425,735,745,849,061,300,000,000,000,000,000,000,000.00/yr

JNJ

Annual income on $10K today (after 15% tax)

$285.83/yr

After 10yr DRIP, annual income (after tax)

$703.61/yr

At 15% tax rate, VIAP beats the other by $425,735,745,849,061,300,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VIAP + JNJ for your $10,000?

VIAP: 50%JNJ: 50%

100% JNJ50/50100% VIAP

Portfolio after 10yr

$2.505559514774322e+32M

Annual income

$250,432,791,675,918,420,000,000,000,000,000,000,000.00/yr

Blended yield

99.95%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

VIAP

No analyst data

Altman Z

-338.9

Piotroski

1/9

JNJ

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$228.73

+55.1% upside vs current

Range: $190.00 — $265.00

Altman Z

5.2

Piotroski

4/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VIAP buys

JNJ buys

No recent congressional trades found for VIAP or JNJ in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricVIAPJNJ

Forward yield	400000.00% ✓	3.36%
Annual dividend / share	$2.00	$4.96 ✓
Payout ratio	50% ✓	55%
1-year div growth	0%	4.2% ✓
5-year div CAGR	0%	5.8% ✓
Portfolio after 10y	$5.011119029548644e+32M	$20.0K ✓
Annual income after 10y	$500,865,583,351,836,840,000,000,000,000,000,000,000.00 ✓	$827.78
Total dividends collected	$5.010957816668433e+32M	$5.6K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	Healthcare

Year-by-year: VIAP vs JNJ ($10,000, DRIP)

Year	VIAP Portfolio	VIAP Income/yr	JNJ Portfolio	JNJ Income/yr	Gap
1← crossover	$40,010,700	$40,000,000.00	$10,676	$355.77	+$40.00M → VIAP
2	$149,615,521,729	$149,572,710,280.37	$11,407	$389.39	+$149615.51M → VIAP
3	$522,880,052,725,200	$522,719,964,116,949.25	$12,198	$426.53	+$522880052.71M → VIAP
4	$1,707,862,989,289,045,000	$1,707,303,507,632,628,700.00	$13,056	$467.62	+$1707862989289.03M → VIAP
5	$5,213,509,402,845,684,000,000	$5,211,681,989,447,144,000,000.00	$13,987	$513.12	+$5213509402845684.00M → VIAP
6	$14,874,219,058,409,543,000,000,000	$14,868,640,603,348,497,000,000,000.00	$14,998	$563.56	+$14874219058409543680.00M → VIAP
7	$39,661,196,234,050,755,000,000,000,000	$39,645,280,819,658,260,000,000,000,000.00	$16,098	$619.52	+$3.966119623405075e+22M → VIAP
8	$98,838,436,350,327,300,000,000,000,000,000	$98,795,998,870,356,880,000,000,000,000,000.00	$17,295	$681.69	+$9.88384363503273e+25M → VIAP
9	$230,205,236,474,344,900,000,000,000,000,000,000	$230,099,479,347,450,050,000,000,000,000,000,000.00	$18,599	$750.82	+$2.302052364743449e+29M → VIAP
10	$501,111,902,954,864,400,000,000,000,000,000,000,000	$500,865,583,351,836,840,000,000,000,000,000,000,000.00	$20,022	$827.78	+$5.011119029548644e+32M → VIAP

VIAP vs JNJ: Complete Analysis 2026

VIAP — Stock

VIA Pharmaceuticals, Inc., a development stage biotechnology company, focuses on the development of compounds for the treatment of cardiovascular and metabolic diseases. It is developing a pipeline of small molecule drugs that target the underlying causes of cardiovascular and metabolic diseases, including vascular inflammation, high cholesterol, high triglycerides, and insulin sensitization/diabetes. The company's drug development pipeline includes VIA-3196, a Phase-1 ready liver-directed thyroid hormone receptor (THR) beta agonist that targets dyslipidemia, such as high LDL cholesterol, high triglycerides, and elevated Lp(a); Diacylglycerol Acyl Transferase 1 (DGAT1) inhibitor, which is in pre-clinical development stage treatment of type 2 diabetes with upside potential in weight control and dyslipidemia; and VIA-2291, a 5-Lipoxygenase inhibitor that has completed third Phase 2 clinical trial for the treatment of atherosclerotic plaque, an underlying cause of heart attack, stroke, and other vascular diseases. VIA Pharmaceuticals, Inc. has two research, development, and commercialization agreements with Hoffman-LaRoche Inc. and Hoffman-LaRoche Ltd. for THR beta agonist; and multiple compounds from preclinical DGAT1 metabolic disorders program. The company was founded in 2004 and is headquartered in San Francisco, California.

Full VIAP Calculator →

JNJ — Healthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →

📬

Get this VIAP vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VIAP vs SCHD VIAP vs JEPI VIAP vs O VIAP vs KO VIAP vs MAIN VIAP vs ABBV VIAP vs MRK VIAP vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.